NCT05817929 Angiopoietin and Adverse Outcomes in Cardiac Surgery
| NCT ID | NCT05817929 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Cardiac Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-03-23 |
| Primary Completion | 2026-04 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.
Eligibility Criteria
Inclusion Criteria: * adult patient scheduled for cardiac surgery under cardiopulmonary bypass Exclusion Criteria: * patient less than 18 years old, * redo surgery, * urgent surgery, * endocarditis, * aortic root repair surgery * aortic dissection * heart beating surgery, * heart transplantation